cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Incyte Corporation
10 own
10 watching
Current Price
$85.7
$-0.31
(-0.36%)
logo-incy
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
19,064.38M
52-Week High
52-Week High
86.29
52-Week Low
52-Week Low
65.07
Average Volume
Average Volume
0.93M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
36.3859
iconMarket Capitalization19,064.38M
icon52-Week High86.29
icon52-Week Low65.07
iconAverage Volume0.93M
iconDividend Yield--
iconP/E Ratio36.3859
What does the Incyte Corporation do?
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Read More
How much money does Incyte Corporation make?
News & Events about Incyte Corporation.
Ticker Report
20days ago
Incyte Co. (NASDAQ:INCY Get Rating) EVP Steven H. Stein sold 28,399 shares of Incyte stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $79.78, for a total transaction of $2,265,672.22. Following the sale, the executive vice president now directly ...
Zolmax
29days ago
Incyte Co. (NASDAQ:INCY Get Rating) EVP Vijay K. Iyengar sold 17,324 shares of the stock in a transaction that occurred on Friday, December 23rd. The stock was sold at an average price of $80.80, for a total value of $1,399,779.20. Following the sale, the executive vice president now directly owns ...
Ticker Report
1month ago
Shares of Incyte Co. (NASDAQ:INCY Get Rating) have been assigned a consensus recommendation of Hold from the twelve research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold ...
Zolmax
1month ago
Incyte Co. (NASDAQ:INCY Get Rating) has been given an average rating of Hold by the twelve ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the...
Business Wire
1month ago
Incyte (NASDAQ:INCY) and CMS Aesthetics, a dermatology medical aesthetic company and subsidiary of CMS (HKEX: 00867), today announced that the companies have entered into a Collaboration and License Agreement for the development and commercialization of ruxolitinib cream, a novel cream formulation...
Frequently Asked Questions
Frequently Asked Questions
What is Incyte Corporation share price today?
plus_minus_icon
Can Indians buy Incyte Corporation shares?
plus_minus_icon
How can I buy Incyte Corporation shares from India?
plus_minus_icon
Can Fractional shares of Incyte Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Incyte Corporation stocks?
plus_minus_icon
What is today’s traded volume of Incyte Corporation?
plus_minus_icon
What is today’s market capitalisation of Incyte Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Incyte Corporation?
plus_minus_icon
What percentage is Incyte Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Incyte Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$85.7
$-0.31
(-0.36%)
logo-incy
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00